Relative Bioavailability of Olodaterol and Fluconazole

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol

Condition or disease	Intervention/treatment	Phase
Healthy; Pulmonary Disease, Chronic Obstructive	Drug: BI 1744; Drug: Fluconazole	Phase 1

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	35 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Relative Bioavailability of 10 mcg Olodaterol (Solution for Inhalation Administered With the Respimat) at Steady State Alone or in Combination With Multiple Doses of 400 mg q.d. Fluconazole (Hard Capsule) in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)
Study Start Date :	May 2010
Actual Primary Completion Date :	July 2010

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Olodaterol	Drug: BI 1744; 10 mcg solution for oral inhalation
Experimental: Olodaterol + Fluconazole	Drug: BI 1744; 10 mcg solution for oral inhalation; Drug: Fluconazole; 400 mg capsule

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss) [ Time Frame: Day 8 of period 1 and day 14 of period 2 ]
   AUC0-6,ss represents the area under the concentration curve of olodaterol in plasma from 0 to time t=6 hours at steady state, where t is defined as the latest time-point where at least 2/3 of the subjects in both treatment periods reveal quantifiable plasma concentrations of olodaterol. The geometric mean is actually the adjusted geometric mean. The geometric coefficient of variation (gCV) is the intra-individual gCV.
2. Maximum Concentration at Steady State (Cmax,ss) [ Time Frame: Day 8 of period 1 and day 14 of period 2 ]
   Cmax,ss represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state. The geometric mean is actually the adjusted geometric mean. The geometric coefficient of variation (gCV) is the intra-individual gCV.

Secondary Outcome Measures :

1. Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss) [ Time Frame: Day 8 of period 1 and day 14 of period 2 ]
   tmax,ss represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide in plasma at steady state.
2. Fraction of Urine Excretion From 0 to 24 Hours at Steady State (fe0-24,ss) [ Time Frame: Day 8 of period 1 and day 14 of period 2 ]
   fe0-24,ss represents the fraction of olodaterol eliminated in urine from time point 0 to 24 hours after administration at steady state.
3. Amount of the Analyte Excreted in Urine From 0 to 24 Hours at Steady State (Ae0-24,ss) [ Time Frame: Day 8 of period 1 and day 14 of period 2 ]
   Ae0-24,ss represents the amount of olodaterol and olodaterol glucuronide excreted in urine from 0 to time t=24 at steady state. The geometric mean is actually the adjusted geometric mean. The geometric coefficient of variation (gCV) is the intra-individual gCV.
4. Area Under Curve From 0 to 12 Hours at Steady State (AUC0-12,ss) [ Time Frame: Day 8 of period 1 and day 14 of period 2 ]
   AUC0-12,ss represents the area under the concentration curve of olodaterol glucuronide in plasma from 0 to time t=12 at steady state, where t is defined as the latest timepoint where at least 2/3 of the subjects in both treatment periods reveal quantifiable plasma concentrations of the analyte. The geometric mean is actually the adjusted geometric mean. The geometric coefficient of variation (gCV) is the intra-individual gCV.
5. Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG [ Time Frame: First administration of trial medication until 6 days after last administration of trial medication ]
   Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
6. Assessment of Tolerability by the Investigator [ Time Frame: End of period 1 and end of period 2 ]
   The investigator assessed tolerability based on adverse events and the laboratory evaluation at the end-of-trial examination. The investigator classified the overall tolerability according to the categories 'good', 'satisfactory', 'not satisfactory', and 'bad'.

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	21 Years to 50 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion criteria:

Healthy male and female volunteers

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Germany
1222.48.1 Boehringer Ingelheim Investigational Site
Berlin, Germany

Sponsors and Collaborators

Boehringer Ingelheim

Investigators

Study Chair:	Boehringer Ingelheim	Boehringer Ingelheim

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier:	NCT01153724 History of Changes
Other Study ID Numbers:	1222.48; 2010-018528-18 ( EudraCT Number: EudraCT )
First Posted:	June 30, 2010
Results First Posted:	June 10, 2014
Last Update Posted:	June 10, 2014
Last Verified:	May 2014

Additional relevant MeSH terms:

Lung Diseases; Chronic Disease; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Disease Attributes; Pathologic Processes; Lung Diseases, Obstructive; Fluconazole; Olodaterol; Antifungal Agents; Anti-Infective Agents; 14-alpha Demethylase Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action

Steroid Synthesis Inhibitors; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors; Bronchodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Anti-Asthmatic Agents; Respiratory System Agents; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic Agonists; Adrenergic Agents